Sign In  |  Register  |  About Pleasanton  |  Contact Us

Pleasanton, CA
September 01, 2020 1:32pm
7-Day Forecast | Traffic
  • Search Hotels in Pleasanton

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Aldeyra Therapeutics to Participate in Upcoming Conferences

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra or the Company), a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in the following investor conferences:

  • Berenberg US CEO Conference

    Format: Analyst-Hosted Fireside Chat

    Date: Wednesday, November 10, 2021

    Time: 10:00 a.m. ET

    Note: A live and recorded webcast of this event will be available on the Investors & Media page of the Company’s website at https://ir.aldeyra.com/. The recorded webcast will be archived and available for 90 days.
  • Eyecelerator@AAO 2021

    Format: Retina Showcase Presentation

    Date: Thursday, November 11, 2021

    Time: 1:05 p.m. CT (2:05 p.m. ET)
  • Jefferies London Healthcare Conference

    Format: Analyst-Hosted Fireside Chat

    Time: Available On Demand Beginning at 8:00 a.m. GMT (3:00 a.m. ET) Thursday, November 18, 2021

    Note: A webcast of this event will be available on the Investors & Media page of the Company’s website at https://ir.aldeyra.com/. The recorded webcast will be archived and available for 90 days.
  • Ophthalmology Day at BTIG

    Format: Analyst-Hosted Fireside Chat

    Date: Tuesday, November 30, 2021

    Time: 1:00 p.m. ET

About Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics, Inc. is a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases. Two of the Company’s lead product candidates, reproxalap and ADX-629, target RASP, which are pre-cytokine, systems-based mediators of inflammation. Reproxalap is being evaluated in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. The Company’s clinical pipeline also includes ADX-2191 (methotrexate for intravitreal injection), a drug candidate in Phase 3 testing for the prevention of proliferative vitreoretinopathy. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.

Contacts

Corporate Contact:

Joshua Reed

Aldeyra Therapeutics, Inc.

Tel: 781-761-4904 ext. 218

jreed@aldeyra.com

Investor & Media Contact:

Scott Solomon

Sharon Merrill Associates, Inc.

Tel: 617-542-5300

ALDX@investorrelations.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Photography by Christophe Tomatis
Copyright © 2010-2020 Pleasanton.com & California Media Partners, LLC. All rights reserved.